Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3144 results

Sort By:

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Study ID: NCT06801223
Start Date: 2026-10-30
End Date: 2028-05-20
Study Type

Interventional

Study Phase

Phase1

No. of Participants

48

Intervention / Treatment

Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)

Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)

Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)

Sponsor

Innoviva Specialty Therapeutics

Source: clinicaltrials.gov

Share:
Add to list

GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

Study ID: NCT07407504
Start Date: 2026-03-14
End Date: 2029-02-21
Study Type

Interventional

Study Phase

Phase1

No. of Participants

186

Intervention / Treatment

GenSci145 tablets

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

Study ID: NCT07448155
Start Date: 2026-03-19
End Date: 2026-05-23
Study Type

Interventional

Study Phase

Phase1

No. of Participants

72

Intervention / Treatment

Ynessa033989

Sponsor

Incyte Corporation

Source: clinicaltrials.gov

Share:
Add to list

The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation

Study ID: NCT07406685
Start Date: 2026-03-17
End Date: 2030-09-17
Study Type

Interventional

Study Phase

Phase4

No. of Participants

52

Intervention / Treatment

Ibandronate IV

Zoledronic acid IV

Sponsor

National Taiwan University Hospital

Source: clinicaltrials.gov

Share:
Add to list

REctus Sheath Trial

Study ID: NCT07068243
Start Date: 2026-05
End Date: 2026-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

25

Intervention / Treatment

1.0% lidocaine with epinephrine (1:100,000)

Sponsor

Duke University

Source: clinicaltrials.gov

Share:
Add to list

A Study to Assess the Safety and Tolerabiliy of SR-878 in Patients With Rheumatoid Arthritis

Study ID: NCT07433335
Start Date: 2026-03-15
End Date: 2028-02-29
Study Type

Interventional

Study Phase

Phase1

No. of Participants

27

Intervention / Treatment

SR-878

Sponsor

SciRhom GmbH

Source: clinicaltrials.gov

Share:
Add to list

Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments

Study ID: NCT06976840
Start Date: 2026-04
End Date: 2030-08-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

200

Intervention / Treatment

Intermittent theta burst stimulation

Sham theta burst stimulation

Continuous theta burst stimulation

Sponsor

Marta Peciña, MD PhD

Source: clinicaltrials.gov

Share:
Add to list

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

Study ID: NCT05909488
Start Date: 2026-05
End Date: 2027-09
Study Type

Interventional

Study Phase

Phase3

No. of Participants

30

Intervention / Treatment

1.5 x 10^6 UC-MSC + CM

5 x 10^6 UC-MSC + CM

Sponsor

PT. Prodia Stem Cell Indonesia

Source: clinicaltrials.gov

Share:
Add to list

Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial

Study ID: NCT04980703
Start Date: 2027-07-01
End Date: 2029-07-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

102

Intervention / Treatment

Grain moxibustion

Sham grain moxibustion

Standard care

Sponsor

Shanghai Institute of Acupuncture, Moxibustion and Meridian

Source: clinicaltrials.gov

Share:
Add to list

Immunotherapy Master Trial for Advanced Cancers

Study ID: NCT07431073
Start Date: 2026-04
End Date: 2034-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

275

Intervention / Treatment

METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each

Sponsor

UNICANCER

Source: clinicaltrials.gov

Share:
Add to list